BACKGROUND: Optimizing quality of life is a major goal for patients with unresectable pancreatic cancer and distal cholangiocarcinoma. The aim of this study was to assess the value of robotic surgery for palliation in these patients. METHODS: Between May 2007 and January 2010, nine patients who presented with unresectable pancreatic cancer or distal cholangiocarcinoma at exploratory laparoscopy were included in this retrospective study. RESULTS: Eight hepaticojejunostomies, one choledochoduodenostomy and five gastrojejunostomies were performed robotically. Mean operative time was 236 ± 25 min. Median length of stay was 6 (range 4-10) days. There was no perioperative mortality. The morbidity rate was 22.2%. After a median follow-up of 265 days, there were no other readmissions for problems related to the operation. CONCLUSIONS: Robotic palliation in cases of unresectable pancreatic cancer or distal cholangiocarcinoma is feasible and effective. The use of robotics in palliative surgery offers low morbidity, short hospital stay and minimal readmissions.
BACKGROUND: Optimizing quality of life is a major goal for patients with unresectable pancreatic cancer and distal cholangiocarcinoma. The aim of this study was to assess the value of robotic surgery for palliation in these patients. METHODS: Between May 2007 and January 2010, nine patients who presented with unresectable pancreatic cancer or distal cholangiocarcinoma at exploratory laparoscopy were included in this retrospective study. RESULTS: Eight hepaticojejunostomies, one choledochoduodenostomy and five gastrojejunostomies were performed robotically. Mean operative time was 236 ± 25 min. Median length of stay was 6 (range 4-10) days. There was no perioperative mortality. The morbidity rate was 22.2%. After a median follow-up of 265 days, there were no other readmissions for problems related to the operation. CONCLUSIONS: Robotic palliation in cases of unresectable pancreatic cancer or distal cholangiocarcinoma is feasible and effective. The use of robotics in palliative surgery offers low morbidity, short hospital stay and minimal readmissions.
Authors: Amir Szold; Roberto Bergamaschi; Ivo Broeders; Jenny Dankelman; Antonello Forgione; Thomas Langø; Andreas Melzer; Yoav Mintz; Salvador Morales-Conde; Michael Rhodes; Richard Satava; Chung-Ngai Tang; Ramon Vilallonga Journal: Surg Endosc Date: 2014-11-08 Impact factor: 4.584
Authors: Nicolas C Buchs; François Pugin; Pascal Bucher; Monika E Hagen; Gilles Chassot; Pascale Koutny-Fong; Philippe Morel Journal: Surg Endosc Date: 2011-11-02 Impact factor: 4.584
Authors: Gustavo Kohan; Carlos G Ocampo; Hugo I Zandalazini; Roberto Klappenbach; Federico Yazyi; Ornella Ditulio; Adelina Coturel; Carlos Canullán; Luis T Chiappetta Porras; Juan Alvarez Rodriguez Journal: Surg Endosc Date: 2014-10-11 Impact factor: 4.584